Current Report Filing (8-k)
November 13 2018 - 11:52AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 13, 2018
Cocrystal
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38418
|
|
35-2528215
|
(State
or other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
19805
N. Creek Parkway
Bothell,
WA
|
|
98011
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (786)-459-1831
Former
name or former address, if changed since last report: 1860 Montreal Road, Tucker GA 30084
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01
|
Regulation
FD Disclosure
|
On
November 13, 2018, Dr. Sam Lee, President of Cocrystal Pharma, Inc. (the “Company”), delivered a presentation
on the preclinical characterization of CC-42344, a broad spectrum, influenza A PB2 inhibitor, at the 6
th
ISRV AVG Conference
in Washington, DC. A copy of the presentation is being furnished as Exhibit 99.1 hereto and is hereby incorporated by reference.
The
information in this Current Report on Form 8-K (including exhibits hereto) shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities
under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities
Act of 1933, or the Exchange Act.
Item
9.01
|
Financial
Statements and Exhibits
|
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Cocrystal
Pharma, Inc.
|
|
|
|
Date:
November 13, 2018
|
By:
|
/s/
James Martin
|
|
Name:
|
James
Martin
|
|
Title:
|
Chief
Financial Officer
|
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024